• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almac Lands $12 Million New Contracts in May

Almac Lands $12 Million New Contracts in May

June 2, 2008
CenterWatch Staff

Yardley, Pa.-based eClinical technology company Almac Clinical Technologies won $12 million in new clinical trial contracts in May. The company will be running a large global study enrolling 20,000 patients, the largest trial for Almac to date. The company said it has seen an increase in the size and intricacy of clinical trials, as well as small complicated trials using adaptive design techniques.

“We are able to handle these through our highly customizable and configurable IXR interactive voice and web response systems. We are also experiencing higher volumes of studies that fit our IXR Express offering, which provides flexible core module-based solutions that enable faster set-up times and lower costs for a web and phone solution,” said Almac’s business development director, Joe Cunningham.

During the 2008 Partnerships with CROs and EDC & Beyond Conference, held in Las Vegas in April, Fritz Haas, vice president of new products and services, spoke about the adoption of electronic data capture (EDC) reaching a "tipping point" in the industry. 

"In the past, EDC was looked upon mainly as a solution for late stage trials involving large volumes of data or complex designs. Today, however, sponsors are adopting early stage methodologies such as translational medicine and 'learn and confirm,' which require data sharing between scientists and clinicians involved in early stage development from discovery through proof-of-concept in phase II," he said.

Almac also signed a new agreement with Boston-based biotech firm Biogen Idec for the use of Almac Diagnostics’ genetic extraction services being used in a phase II trial for gastrointestinal stromal tumors.

Julie Ranuio-Kelley, senior associate scientist for Biogen Idec, touted the benefits of using Almac's extraction sevices in discovering useful new development tools.

“This newly validated approach means that we can now access the full genetic information contained in our clinical trial samples. This will allow us to uncover biomarkers that will help us discover additional drug candidates and identify specific patient populations that will benefit from a particular treatment,” she said.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing